Stock Analiz

Can-Fite BioPharma Ltd. CANF

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.42Market cap $4M
Open the interactive analysis →

Can-Fite BioPharma Ltd. (CANF) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to June 30, 2026 it had revenue of $405000 and net income of -$10M, a net margin of -2358.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -121%.

About Can-Fite BioPharma

Can-Fite BioPharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $789000 in 2017 to $405000 in 2025, a decline of about 8.0% a year. It was profitable in 1 of the last 10 years in our data. It spends 1653% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S10.6
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-221.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-39.9%
Revenue growth (5 yrs, per year)-11.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1471.6%
ROIC (5-yr avg.)-120.7%
Profitable years (of last 10)1
Years paying a dividend2

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$405000$405000$674000$743000$810000$853000$763000$2M$4M$789000—
Net income-$10M-$10M-$8M-$8M-$10M-$13M-$14M-$13M-$7M-$6M$8M
Free cash flow-$10M-$9M-$8M-$8M-$11M-$10M-$12M-$11M-$4M-$9M-$9M
EPS (diluted)$-3.15$-3.24$-2.60$-2.52$-3.36$-4.16$-4.76$-4.16$-2.17$-2.09$2.72
Net margin-2358.8%-2426.7%-1169.1%-1027.5%-1255.9%-1478.9%-1892.9%-621.3%-172.0%-803.4%—
ROIC—-138.8%-115.9%-103.0%-175.9%-69.9%-181.9%-376.9%-141.9%-190.2%-115.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $8.00, 463% above the current price; targets range from $8.00 to $8.00; the consensus rating is “none”; expected EPS is $-2.04 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Can-Fite BioPharma pay a dividend?

Not currently.

Is Can-Fite BioPharma a good stock to buy?

We do not give buy or sell advice. Can-Fite BioPharma scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.